Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAR566658 |
Synonyms | |
Therapy Description |
SAR566658 is a monoclonal antibody against CA6 in conjugation with maytansinoid, which may deliver targeted cytotoxicity to MUC-1 over expressing tumor cells (J Clin Oncol 34, 2016 (suppl; abstr 2511), PMID: 32451330). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR566658 | SAR-566658 | SAR566658 is a monoclonal antibody against CA6 in conjugation with maytansinoid, which may deliver targeted cytotoxicity to MUC-1 over expressing tumor cells (J Clin Oncol 34, 2016 (suppl; abstr 2511), PMID: 32451330). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02984683 | Phase II | SAR566658 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | Terminated | NLD | ITA | ESP | CZE | BEL | 0 |